|
Golimumab Clinical Trials
3 actively recruiting trials across 3 locations
▲ +1 trial since June 2026
Also known as: CNTO 148, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer, Simponi
Pipeline
Phase 2: 1Phase 3: 2
Top Sponsors
- University of Pennsylvania1
- University of Nebraska1
- NYU Langone Health1
Loxahatchee Groves, Florida1 trial
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Family Arthritis Center
Phase 3
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
New York, New York1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.